DeisenhammerFZetterbergHFitznerB, et al. The cerebrospinal fluid in multiple sclerosis. Front Immunol2019; 10: 726.
2.
PavlasovaGMrazM.The regulation and function of CD20: An “enigma” of B-cell biology and targeted therapy. Haematologica2020; 105: 1494–1506.
3.
SchuhEBererKMulazzaniM, et al. Features of human CD3+CD20+ T cells. J Immunol2016: 197: 1111–1117.
4.
CreeBAC. All anti-CD20 monoclonal antibodies have similar efficacy and safety risks – Yes. Mult Scler J2022.
5.
SellebjergFCJ. All anti-CD20 monoclonal antibodies have similar efficacy and risks – No. Mult Scler J2022.
6.
AshaMZIAl-AsaadYKhalilSFH.The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis. IBRO Neurosci Rep2021; 11: 103–111.
7.
SamjooIAKlotzLGiovannoniG, et al. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis. Mult Scler Relat Disord2022; 66: 104031.
8.
DunnNJutoARynerM, et al. Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. Mult Scler2018; 24: 1224–1233.
9.
CobanHGermaineSDimaandalI, et al. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population. Mult Scler Relat Disord2021; 53: 103021.
10.
CobanHSiddiquiACreedMA, et al. Preventive neurology concepts for training the next-generation and closing gaps in real-world Multiple Sclerosis Care. Mult Scler Relat Disord2021; 47: 102631.
